Targeted genetic engineering of human pluripotent cells is a prerequisite for exploiting their full potential. Such genetic manipulations can be achieved using site-specific nucleases.
Here we engineered transcription activator-like effector nucleases (TALENs) for five distinct genomic loci. At all loci tested we obtained human embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) clones carrying transgenic cassettes solely at the TALEN-specified location. Our data suggest that TALENs employing the specific architectures described here mediate site-specific genome modification in human pluripotent cells with similar efficiency and precision as do zinc-finger nucleases (ZFNs).
Gene targeting of human pluripotent cells by homologous recombination is inefficient, which has impeded the use of human ESCs and iPSCs in disease models. To overcome this limitation, we and others have shown that ZFNs can be used to modify the genomes of ESCs and iPSCs [1] [2] [3] . ZFNs can be engineered to induce a double-strand break precisely at a predetermined position in the genome 4 . The double-strand break can be repaired through nonhomologous end-joining to drive targeted gene disruption or through the homology-directed DNA repair pathway using an exogenous donor plasmid as a template. Depending on the donor design, this repair reaction can be used to generate large-scale deletions, gene disruptions, DNA addition 4 or single-nucleotide changes 5 .
Recent work on transcription activator-like effectors (TALEs) provides an alternative approach to the design of site-specific nucleases 6 . Natural TALEs are transcription factors used by plant pathogens to subvert host genome regulatory networks 6 . The DNA-binding domain of TALEs is unusual. Multiple units of ~34 amino acids (called TALE repeats) are arranged in tandem, their sequence nearly identical except for two highly variable amino acids that establish the base-recognition specificity of each unit 7, 8 . Each individual domain determines the specificity of binding to one DNA base pair in the TALE recognition sequence, and therefore arrays of four different repeat units are sufficient to generate TALEs with novel DNA recognition sites 7, 8 . Nucleases based on such engineered TALE domains have been shown to target endogenous genes in trans-formed human cells 9, 10 . Here we evaluate the use of TALENs for genetic engineering of endogenous loci in human ESCs and iPSCs.
We designed TALENs targeting the PPP1R12C (the AAVS1 locus), OCT4 (also known as POU5F1) and PITX3 genes at precisely the same positions as targeted earlier by ZFNs 2 . TALEN expression constructs and corresponding donor plasmids bearing homologous sequences were introduced into ESCs (line WIBR#3) 11 and iPSCs (line C1) 12 by electroporation ( Supplementary Fig. 1 and Supplementary Tables 1 and 2) . Southern blot analysis was used to identify correctly targeted clones.
We targeted PPP1R12C with a gene trap approach (expressing puromycin (Puro) from the endogenous gene; Fig. 1a ,b and Table 1 ) or with an autonomous selection cassette (puromycin expressed from the PGKpromoter ( Fig. 1 , Table 1 and Supplementary Figs. 1-3 ). Targeting efficiency was high and similar to that with ZFNs 2 : 50% of the clones were targeted in one or both alleles and carried no randomly integrated transgenes ( Fig. 1b , Table 1 and Supplementary Fig. 2) . Similarly, an SA-Puro-CAGGS-eGFP transgene was highly expressed from this locus ( Fig. 1a and Supplementary Fig. 3a,b) . Notably, such targeted cells remained pluripotent based on analysis of marker expression and of teratomas. (Supplementary Fig. 3c-e ). Cells of all germ layers in teratomas expressed eGFP, indicating that TALEN-as well as ZFN-mediated targeting of PPP1R12C results in robust transgene expression in pluripotent as well as in differentiated cells ( Supplementary Fig. 3a,b,d,e ).
OCT4 was targeted using three different donor plasmids, resulting in expression of puromycin and an OCT4 exon1-eGFP fusion protein under control of the endogenous OCT4 promoter. The first two donor plasmids were designed to integrate a splice acceptor-eGFP-2A-Puro cassette into the first intron of OCT4, whereas the third donor generated an in-frame fusion of exon 1 with the eGFP-2A-Puro cassette (Supplementary Fig. 4 ). Targeting efficiency in ESCs and iPSCs was 70-100% as determined by Southern blot analysis and DNA sequencing of single cell-derived clones ( Table 1 and Supplementary Figs. 1 and 4) .
We also targeted the first exon of PITX3, which is not expressed in human pluripotent cells, and found that ~6% of drug-resistant clones carried the transgene solely at the PITX3 locus as evaluated by Southern blot analysis ( Table 1 and Supplementary Figs. 1 and 5) . Notably, in one clone the transgene had integrated into both alleles of PITX3.
To target the C terminus of OCT4, which has not been previously targeted by ZFNs, we generated TALENs directed against sequences flanking the stop codon of OCT4 using two donor plasmids: the last OCT4 codon was either fused in frame with an eGFP-PGK-Puro construct or with eGFP preceded by a 2A sequence (2A-eGFP-PGK-Puro; Fig. 1c and Table 1 ). After excision of the LoxP-flanked PGK-Puro cassettes, either a C-terminal OCT4-eGFP fusion protein or a separately translated eGFP protein will be expressed under the control of endogenous OCT4 (ref. 13) . Southern blot analysis showed that 2-10% of single cell-derived ESC and iPSC clones carried the transgene cassette at the OCT4 locus ( Fig. 1d,e and Table 1 ). Cre-mediated excision of the PGK- (Supplementary Fig. 7) , validating eGFP expression as a faithful reporter of OCT4 expression. To illustrate the general utility of TALENs for generating such C-terminal fusion proteins, we designed TALENs that cut at the last coding exon of PITX3 and generated ESCs and iPSCs with an in-frame fusion of 2A-eGFP or eGFP. Targeting was highly efficient, resulting in some clones carrying the transgene on both alleles (Supplementary Fig. 8 and Table 1 ).
Puro cassette from OCT4-eGFP-targeted ESCs resulted in nuclear eGFP fluorescence, whereas clones targeted with OCT4-2A-eGFP showed pan-cellular eGFP fluorescence (Fig. 1g) . Fluorescence was higher in OCT4-2A-eGFP-targeted clones than in OCT4-eGFP-targeted clones as determined by fluorescence-activated cell sorting (FACS) analysis, suggesting different protein stabilities of the OCT4-eGFP fusion protein and eGFP (Supplementary Fig. 6) . A gene trap vector fusing an eGFP-2A-Puro cassette with the last OCT4 codon had a 50% targeting efficiency (Fig. 1c,f,g, Table 1 and Supplementary Fig. 6 ) similar to that The gene targeting efficiencies for OCT4, PPP1R12C and PITX3 (last column) in either ESCs or iPSCs (first column) using the indicated TALEN pairs and donor plasmids and the number of clones analyzed, the number of clones found to carry additional unwanted integrations and the number of either homozygous or heterozygous correctly targeted clones. eHiFi indicates TALENs designed to function as obligatory heterodimers.
B R I E F C O M M U N I C AT I O N S
To assess the frequency of off-target modification not detected by Southern blot analysis, we determined the binding specificity of the PPP1R12C TALENs using systematic evolution of ligands by exponential enrichment. Genotyping of a panel of 19 of the most likely potential off-target sites revealed unintended cleavage at a low frequency ( Supplementary Figs. 9 and 10, Supplementary Tables 3 and 4 and Supplementary notes for detailed description). A strategy to minimize potential off-target events is to design TALENs to function as obligatory heterodimers 14 . Such heterodimeric nucleases, fused to the TALE DNA binding domain, enabled high-efficiency targeting of the PPP1R12C locus ( Table 1) .
Individual TALE repeats can be joined to produce DNA binding domains capable of recognizing endogenous sequences in mammalian cells 9, 10, 15 . In the present work, we have built on the recent development of an efficient TALEN architecture 9 and evaluated the utility of TALENs to drive targeted gene modifications in human ESCs and iPSCs. At all five genomic sites tested, we obtained clones carrying transgenes solely at the TALEN-specified locus at a frequency between 67% and 100% for the first exon of OCT4, between 2% and 46% for the targeting of the OCT4 STOP codon, of about 50% for the AAVS1 locus, between 1% and 13% for the targeting of the ATG of PITX3 and between 19% and 23% for the PITX3 STOP codon. These efficiencies are similar to those observed with ZFNs 2 . As this approach couples a simple DNA recognition code with robust activity in human pluripotent stem cells, our data suggest that TALENs are a useful tool for investigator-specified targeting and genetic modification in human pluripotent cells.
Note: Supplementary information is available on the Nature Biotechnology website.
